Vimarsana
Biggest News Aggregation in the World

Page 6 - Patrick Brenske News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrick Brenske. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrick Brenske Today - Breaking & Trending Today

DGAP-News: MPH Health Care AG: Preliminary IFRS result 2021 - Vimarsana News

DGAP-News: MPH Health Care AG: Preliminary IFRS result 2021

DGAP-News: MPH Health Care AG / Key word(s): Preliminary Results MPH Health Care AG: Preliminary IFRS result 2021 21.04.2022 /...

DGAP-News: Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellence - Vimarsana News

DGAP-News: Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellence

DGAP-News: HAEMATO AG / Key word(s): Personnel Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellence ...

Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellence - Vimarsana News

Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellence

DGAP-News: HAEMATO AG / Key word(s): Personnel28.03.2022 / 18:41 The issuer is solely responsible for the content of this announcement.______________________________________________________________________________Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellenceSchönefeld, 28.03.20...

HAEMATO adds a new generation test device to its portfolio - Vimarsana News

HAEMATO adds a new generation test device to its portfolio

15.02.2022 HAEMATO adds a new generation test device to its portfolio | Corona | HAEMATO | PCR | Pharma | Tests |

Source: dgap.de
Original-Research: HAEMATO AG (von GBC AG) - Vimarsana News

Original-Research: HAEMATO AG (von GBC AG)

Original-Research: HAEMATO AG - von GBC AGEinstufung von GBC AG zu HAEMATO AGUnternehmen: HAEMATO AGISIN: DE000A289VV1Anlass der Studie: Research CommentEmpfehlung: BuyKursziel: 50.10 EURKursziel auf Sicht von: 31.12.2022Letzte Ratingänderung: Analyst: Cosmin Filker; Marcel GoldmannPCR PoC-Device added to the produc...